Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Acthib, Pentacel
Generic Name
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DrugBank Accession Number
DB10076
Background

Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is a vaccine for intramuscular injection used in the prevention of invasive disease caused by Haemophilus influenzae type b. H. influenzae is a Gram-negative coccobacillus that can cause infections including sepsis and meningitis. The vaccine contains the Haemophilus influenzae type b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the H. influenzae type b strain 1482 grown in a semi-synthetic medium, covalently bound to tetanus toxoid 1. The toxoid antigen is purified and toxin-inactivated.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated / Toxoid / Conjugate
Synonyms
  • Haemophilus influenzae type B strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Abatacept.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Acetylsalicylic acid.
AdalimumabThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Altretamine.
Aminosalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Aminosalicylic acid.
AmsacrineThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Anakinra.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ActHIBKit10 ug/0.5mLIntramuscularSanofi Pasteur Inc.1993-03-30Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Act-hibHaemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg)Kit; Powder, for solutionIntramuscularSanofi Pasteur Limited1992-12-31Not applicableCanada flag
MenhibrixHaemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 ug/0.5mL)Injection, powder, lyophilized, for solutionIntramuscularGlaxoSmithKline Biologicals SA2013-09-032013-11-27US flag
MenhibrixHaemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 ug/0.5mL)KitIntramuscularGlaxoSmithKline Biologicals SA2013-09-032017-09-17US flag
PentacelHaemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (20 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5mL)IntramuscularSanofi Pasteur Inc.2008-06-20Not applicableUS flag
PentacelHaemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (20 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (29 [D'ag'U]/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (7 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (26 [D'ag'U]/0.5mL)IntramuscularSanofi Pasteur Inc.2008-06-20Not applicableUS flag
PENTAXIM 0,5 ML (IM ENJEKSİYON) SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETHaemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg/0.5ml) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 mcg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)Injection, powder, for suspensionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
FLV5I5W26R
CAS number
Not Available

References

General References
  1. Dailymed Label: ACTHIB- haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen [Link]
PubChem Substance
347910467
RxNav
1300464

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionDiphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus1
4CompletedTreatmentPain1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionBacterial Infections / Virus Diseases2
3CompletedPreventionDiphtheria / Haemophilus Infections / Pertussis / Poliomyelitis / Tetanus1
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Pertussis / Poliomyelitis / Tetanus2
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Pertussis / Tetanus1
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Whooping Cough1
3CompletedPreventionDiphtheria / Meningitis, Bacterial / Pertussis / Poliomyelitis / Tetanus1
3CompletedPreventionDiphtheria / Pertussis / Poliomyelitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Kit; powder, for solutionIntramuscular
Injection, powder, for solutionIntramuscular
KitIntramuscular10 ug/0.5mL
Injection, powder, lyophilized, for solutionIntramuscular
KitIntramuscular
Injection, powder, for suspensionIntramuscular
Injection, suspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on November 30, 2015 21:23 / Updated on June 12, 2020 16:52